Clinical Infrastructure for Cardiometabolic Medicine

Sometimes the best place
to hide is in plain sight.

Early fatty liver is associated with significant silent heart risk in 35% of US adults. CMiQHealth is the complete clinical system to reveal it and act on it.

See the System Try a Free CMiQ Report
The Clinical Gap

The standard tools weren't built for this.

ALT, AST, and FibroScan are injury and fibrosis instruments. They answer one question: how damaged is the liver already? They were never designed to reveal early fatty liver as a driver of cardiometabolic strain. That's not a clinical failure. It's a tool gap.

80M+
Americans with undetected fatty liver disease
Issa et al., Journal of Hepatology, 2025
+61%
MACE risk at Fatty Liver Index ≥60, even when conventional labs appear completely normal
Zhong et al., Am J Preventive Cardiology, 2026
+85%
Increased all-cause mortality in documented MASLD patients versus matched general population controls
Issa et al., Journal of Hepatology, 2025
What This Means Clinically

Your patients can look completely normal on standard labs and carry significant undetected cardiometabolic strain.

MASLD affects an estimated 80 million Americans. The majority have no idea. Neither do their practitioners. Not because they aren't looking. Because the standard tools don't show it until meaningful physiologic strain has already accumulated.

A patient can present with entirely unremarkable liver enzymes and carry a 61% elevated risk of heart attack, stroke, or cardiovascular death. That's not a rare edge case at the margins of your practice.

That's your next appointment.

"CMiQHealth was built to change that."
The Complete System

A complete clinical infrastructure. Built around one blind spot.

Three components. One integrated system. The only one built specifically around the fatty liver to cardiometabolic niche.

01

CMiQ Panel

A comprehensive cardiovascular, hepatic and metabolic assessment delivered via dried blood spot. The only commercially available cardiometabolic panel that includes the Fatty Liver Index. Baseline and retest panels ship directly to your patient, powered by the Physiologic Strain Model.

02

MLR-90 Protocol

A complete 90-day metabolic reset. BergaPure supplementation, structured lifestyle guidance, and all patient and practitioner assets pre-built and ready to deploy. The only program that includes the proof.

03

CMiQCertified

A geographically exclusive practitioner network built around the fatty liver to cardiometabolic niche. Three practitioners per metro area. Your patients find you through the EndFattyLiver.com directory.

"Three components. One complete system. The only one built specifically around the fatty liver blind spot."

See the Full Program
The Evidence Base

Every element. Peer-reviewed and published.

MLR-90 is not built on clinical consensus or wellness trends. Every element, the assessment markers, the supplementation protocol, and the cardiometabolic risk framework, is anchored to published, peer-reviewed clinical data.

+61%

Increased MACE risk at Fatty Liver Index ≥60, even when conventional cardiometabolic labs appear completely normal. A patient can look unremarkable on standard panels and carry a 61% elevated risk of heart attack, stroke, or cardiovascular death.

Zhong et al., American Journal of Preventive Cardiology, 2026 · PMID: 41624044
+85%

Increased all-cause mortality in documented MASLD patients versus matched general population controls. Population-based study of 13,099 Swedish MASLD patients. Cardiovascular disease, not liver disease, was the highest absolute cause of death.

Issa et al., Journal of Hepatology, 2025 · DOI: 10.1016/j.jhep.2025.03.001
76%

Of patients taking BergaPure showed measurable improvement in liver fat grade over 12 weeks, versus 51% in the placebo group. A double-blind RCT in 102 confirmed hepatic steatosis patients. BergaPure reduced liver fat, LDL-C, HOMA-IR, AST and GGT.

Ferro et al., Frontiers in Endocrinology, 2020 · PMID: 32849284
T2DM + MASLD

In patients with both T2DM and MASLD, BergaPure produced significant reductions in liver fat on ultrasound, improvements in serum fibrosis markers, and measurable reductions in vascular inflammation and oxidative stress versus placebo.

Musolino et al., Journal of Traditional and Complementary Medicine, 2020 · PMID: 32670822

"The science existed. The clinical tool to act on it didn't. Now it does."

Steven Bennett, DC, BSME — Founder, CMiQHealth
Founder
Why This Exists

Built by a clinician who saw the gap.

I spent 17 years in functional medicine watching patients accumulate cardiometabolic strain that nobody was catching early enough. The labs looked normal. The patients didn't feel sick. And then they had an event.

The pattern kept pointing to the same place: the liver. Not the damaged, end-stage liver that FibroScan finds. The early, metabolically active, silently stressed liver that no commercial panel was designed to see.

The problem was significant enough that I launched EndFattyLiver.com to raise public awareness before I had anything to sell. Then I built the clinical infrastructure practitioners actually need.

CMiQHealth is what I wished existed when I was sitting across from those patients. The panel, the protocol, the practitioner network. Built on peer-reviewed science. Designed to reveal what standard tools miss, early enough to matter.

"That's not a product pitch. That's why this exists."

Steven Bennett, DC, BSME
Founder and CEO, CMiQHealth · CardioMetaboliQ Labs, LLC
OnDemand Report Generation

Your patients are arriving with data. CMiQHealth gives you the framework to make it mean something.

Generate a full CMiQ Report from existing data.

The CMiQHealth OnDemand platform lets practitioners generate a full CMiQ Report from existing patient data, whether from a prior DBS draw, a standard lab panel, or a direct-to-consumer test. No new kit required. The Physiologic Strain Model transforms whatever biomarker data you have into a structured, actionable clinical picture.

The DTC lab moment is here. Are you ready for it?

As platforms like Function Health, Superpower, and SiPhox put comprehensive biomarker panels directly in patients' hands, practitioners are increasingly the first call when that data creates more questions than answers. Eight pages of biomarkers and no clinical context is not insight. It's noise. OnDemand gives you a structured interpretation framework to bring clarity, accountability, and clinical meaning to whatever data walks through your door.

Try a Free CMiQ Report
The Practice Opportunity

A niche nobody is serving. A system built to serve it.

The patient population is already in your practice.

One in three of your patients has early fatty liver. They aren't presenting with liver symptoms. They're presenting with fatigue, weight resistance, cardiovascular strain, and metabolic dysfunction that standard panels aren't explaining. CMiQHealth gives you the framework to see what's actually driving it.

The only program that includes the proof.

Every other lab company sells you a panel and transfers clinical responsibility entirely to you. MLR-90 is different. We're confident enough in this niche, and in this protocol, that we sell you the baseline and the retest together. The retest isn't an upsell. It's where the clinical outcome lives. And we've priced the complete program below what a single panel costs at retail, because we want practitioners running the full arc.

Two consultations. Ninety days. A program that runs itself.

MLR-90 is designed around two practitioner-guided results reviews. Everything between them, patient education, check-ins, lifestyle guidance, supplementation, is pre-built and included. Your clinical expertise drives the interpretation. The system handles the rest.